The closing price of Clover Health Investments Corp (NASDAQ: CLOV) was $0.79 for the day, down -3.68% from the previous closing price of $0.82. In other words, the price has decreased by -$0.0302 from its previous closing price. On the day, 8488044 shares were traded. CLOV stock price reached its highest trading level at $0.8298 during the session, while it also had its lowest trading level at $0.7850.
Ratios:
Our analysis of CLOV’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cowen on February 02, 2022, Upgraded its rating to Market Perform and sets its target price to $3 from $7 previously.
On February 02, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $6.
On January 19, 2022, SVB Leerink started tracking the stock assigning a Mkt Perform rating and target price of $3.SVB Leerink initiated its Mkt Perform rating on January 19, 2022, with a $3 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 14 ’24 when Loengard Anna U bought 137,000 shares for $0.73 per share. The transaction valued at 100,010 led to the insider holds 538,841 shares of the business.
Loengard Anna U bought 13,625 shares of CLOV for $9,946 on Mar 14 ’24. The Director now owns 15,125 shares after completing the transaction at $0.73 per share. On Sep 06 ’23, another insider, Loengard Anna U, who serves as the Director of the company, bought 11,000 shares for $1.30 each. As a result, the insider paid 14,300 and bolstered with 10,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 408.62M and an Enterprise Value of 170.59M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.19 while its Price-to-Book (P/B) ratio in mrq is 1.33. Its current Enterprise Value per Revenue stands at 0.08 whereas that against EBITDA is -0.81.
Stock Price History:
Over the past 52 weeks, CLOV has reached a high of $1.63, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is 0.9092, while the 200-Day Moving Average is calculated to be 1.0227.
Shares Statistics:
CLOV traded an average of 9.86M shares per day over the past three months and 15.62M shares per day over the past ten days. A total of 393.27M shares are outstanding, with a floating share count of 374.90M. Insiders hold about 24.03% of the company’s shares, while institutions hold 19.64% stake in the company. Shares short for CLOV as of Feb 29, 2024 were 36.54M with a Short Ratio of 3.71, compared to 27.68M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.49% and a Short% of Float of 9.20%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.07 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.09, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.19 and -$0.27 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$0.2, with 3 analysts recommending between -$0.16 and -$0.25.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $325.59M to a low estimate of $316.1M. As of the current estimate, Clover Health Investments Corp’s year-ago sales were $527.77M, an estimated decrease of -39.10% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $321.13M, a decrease of -37.50% over than the figure of -$39.10% in the same quarter last year. There is a high estimate of $324.99M for the next quarter, whereas the lowest estimate is $315M.
A total of 3 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $1.3B, while the lowest revenue estimate was $1.25B, resulting in an average revenue estimate of $1.28B. In the same quarter a year ago, actual revenue was $2.03B, down -37.30% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $1.34B in the next fiscal year. The high estimate is $1.36B and the low estimate is $1.28B. The average revenue growth estimate for next year is up 4.80% from the average revenue estimate for this year.
